Inter- and Multidisciplinary, Cross-sectoral Feto-neonatal Pathway

Sponsor
Technische Universität Dresden (Other)
Overall Status
Recruiting
CT.gov ID
NCT04514276
Collaborator
Jena University Hospital (Other)
828
2
2
36
414
11.5

Study Details

Study Description

Brief Summary

Due to the fetoneonatal pathway it is possible to identify pregnant women with an increased risk of fetal growth restriction or pre-eclampsia in early stages (from 10th week of pregnancy). Women whose pregnancy is considered high-risk receives risk-adapted prenatal treatment as well as certain treatments for their newborn and infant until 1 year of age. The tasks of all involved persons are defined by standard operating procedures (SOP)

Condition or Disease Intervention/Treatment Phase
  • Other: consecutive fetoneonatal healthcare pathway
N/A

Detailed Description

By implementing a preventive feto-neonatal pathway, healthcare for pregnant women with high risk of fetal growth restriction (FGR) or pre-eclampsia will be improved and, therefore the occurence of children's health problems may be prevented.The pathway allows healthcare to be structured, ross-sectoral, inter- and multidisciplinary in consideration of medical and psychosocial imensions. The feto-neonatal pathway transfers scientific findings, which already determine international routine care, in the project region into clinical routine care. The anamnestically increased risk for FGR or pre-eclampsia is validated by ultrasound and the identified high-risk pregnancy is attended risk-adapted from birth until the end of the first year of life of the child.As a result, the mothers' pregnancy-related risks (death, premature delivery, traumatic stress disorders) as well as risks for the child (prematurity and associated problems, childhood growth restriction with the risk of metabolic syndrome, developmental neurological problems) are reduced and the sustainability of the interventions is ensured in the long term through improved health competence of the families. The feto-neonatal pathway shows how highly specialised fetoneonatal care of high-risk pregnancies can be ensured while ensuring primary care in a health region, and offers the possibility of being extended to other indications.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
828 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Inter- and Multidisciplinary, Cross-sectoral Feto-neonatal Pathway for High-risk Pregnant Women Because of Fetal Growth Restriction
Actual Study Start Date :
Jun 1, 2020
Anticipated Primary Completion Date :
Mar 1, 2022
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: consecutive fetoneonatal healthcare

inclusion criteria: pregnant woman having higher risk of early fetal growth restriction, preeclempsia living in studyregion (east-Saxony or east Thuringia) the fetoneonatal pathway consists of four consecutive parts: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.

Other: consecutive fetoneonatal healthcare pathway
(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.

No Intervention: standard fetoneonatal healthcare

inclusion criteria: due to health insurance data by AOK PPLUS & ikk classics propsensityscorematched pregnant women living in west Saxony and Thuringia, being not part of the intervention group receiving standard health care.

Outcome Measures

Primary Outcome Measures

  1. Evaluation of patients' safety: maternal pre-eclampsia rate [through study completion, an average of 1 year and 7 months]

    self-designed questionnaire, health information

  2. Evaluation of patients' safety: newborn's birthweight adjusted by gestational age [through study completion, an average of 1 year and 7 months]

    self-designed questionnaire, health information

  3. Evaluation of patients' safety: maternal morbidity [through study completion, an average of 1 year and 7 months]

    self-designed questionnaire, health information

  4. Evaluation of patients' safety: infantil morbidity [through study completion, an average of 1 year and 7 months]

    self-designed questionnaire, health information

  5. Evaluation of patients' safety: Quality of life [through study completion, an average of 1 year and 7 months]

    Questionnaire: Quality of Life (Angermayer, Kilin & Matschinger, 2000)

  6. Evaluation of patients' safety: attachment behavior [through study completion, an average of 1 year and 7 months]

    Questionnaire: Postpartum Bonding Questionnaire (Reck et al., 2006)

  7. Evaluation of patient's access to treatment and satisfaction [through study completion, an average of 1 year and 7 months]

    self-designed questionnaire

  8. claim of the health services [From admission to discharge, study inclusion to one year postpartum)]

    based on self-designed questionnaires

  9. prohibition of employment [From admission to discharge, study inclusion to one year postpartum)]

    based on self-designed questionnaires

  10. duration of unemployability [From admission to discharge, study inclusion to one year postpartum)]

    based on self-designed questionnaires

Secondary Outcome Measures

  1. health economical evaluation [From admission to discharge, study inclusion to one year postpartum]

    cost-benefit-analysis of patients' outcome in relation to supply costs based on secondary data provided by Health insurance funds

  2. evaluation of ungoing processes during the fetoneontal health care pathway: target patients [From admission to discharge, study inclusion to one year postpartum]

    based on secondary data provided by Health insurance funds

  3. evaluation of ungoing processes during the fetoneontal health care pathway: effectiveness of fetoneonatal health care [From admission to discharge, study inclusion to one year postpartum]

    based on secondary data provided by Health insurance funds

  4. evaluation of ungoing processes during the fetoneontal health care pathway: participation of health care provider [From admission to discharge, study inclusion to one year postpartum]

    based on secondary data provided by Health insurance funds

  5. evaluation of ungoing processes during the fetoneontal health care pathway: implementation of participating employees [From admission to discharge, study inclusion to one year postpartum]

    based on secondary data provided by Health insurance funds

  6. evaluation of ungoing processes during the fetoneontal health care pathway: the pathway's maintenance being long term part of routine health care [From admission to discharge, study inclusion to one year postpartum]

    based on secondary data provided by Health insurance funds

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female, minim. 10 weeks of pregnancy, maximum 36 weeks of pregnancy

  • anamnestic risk of preeclempsia or fetal growth restriction

  • being part of the project region

Exclusion Criteria:
  • none

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medizinische Fakultät Dresden Klinik und Poliklinik für Kinder- und Jugendmedizin / Neonatologie & Pädiatrische Intensivmedizin Dresden Saxony Germany 01307
2 Universitätsklinikum Jena Klinik für Kinder- und Jugendmedizin Jena Thuringia Germany 07747

Sponsors and Collaborators

  • Technische Universität Dresden
  • Jena University Hospital

Investigators

  • Study Director: Mario Rüdiger, Prof. Dr, Technische Univeristät Dresden

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT04514276
Other Study ID Numbers:
  • FetoNeonatPfad
First Posted:
Aug 14, 2020
Last Update Posted:
Aug 23, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2021